MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2024
November 25, 2024
Our vision is to become a leading pharmaceutical company within the U.S., offering a growing portfolio of products that improve patients' lives.
At Medicure, we are focused on improving the health of patients by offering a growing portfolio of products and services and ensuring all patients get access to care they need.
At Medicure, our mission is to serve patients by delivering safe and efficacious life-changing medicines
Medicure's Phase 3 clinical trial aims to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.
A conference call will be held Tuesday, November 26, 2024 at 7:30am CT (8:30 ET)
Medicure Inc.– via Marley Drug, creates a direct-to-consumer e-commerce pharmacy solution. The service is available in all 50 states and can fulfill a formulary of over 100 prescription medications.
Leadership
Board of Directors
Our History
Mission and Values
Medicure Marks Its 25th Anniversary
People and Culture
Careers
AGGRASTAT® (tirofiban HCl) injection
Zypitamag®
Pipeline
Drug Safety
Medical Information
Patient Information
Events
Presentations / Conference Calls
Stock Information
Annual Reports
Quarterly Reports
Corporate Governance
Investor Contacts
Copyright © 2025 Medicure Inc. All Rights Reserved. | Privacy Statement